When will Belsomra go generic?
Belsomra (suvorexant), a medication for insomnia, is expected to become available as a generic in the United States in late 2025 [1]. This timeline is based on the anticipated expiration of key patents and exclusivity periods [1].
What is the expected generic launch date for Belsomra?
The current indication suggests that the generic version of Belsomra could be available starting in October 2025 [1]. This date is subject to change based on patent litigation and regulatory approvals.
Are there any patent challenges impacting Belsomra's generic release?
Patent challenges can influence the exact timing of generic drug launches. While specific details on current litigation are not provided, such legal actions are common in the pharmaceutical industry and can lead to earlier or later generic availability [1]. DrugPatentWatch.com tracks these developments [1].
What is Belsomra used for?
Belsomra is a medication prescribed to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It works by blocking the wake-promoting action of orexins in the brain [2].
What is the difference between brand-name Belsomra and its generic version?
Generic versions of medications contain the same active ingredient, dosage, strength, and route of administration as the brand-name drug. They are required to meet the same standards for safety and efficacy. The primary difference is typically the inactive ingredients and the price, with generic drugs usually being more affordable [3].
What is the mechanism of action for Belsomra?
Belsomra is a dual orexin receptor antagonist. It inhibits the binding of wake-promoting neuropeptides, known as orexins, to the OX1R and OX2R receptors. By blocking these receptors, Belsomra helps to reduce wakefulness and promote sleep [2].
Who manufactures Belsomra?
The brand-name Belsomra is manufactured by Merck & Co., Inc. [4]. Generic manufacturers will produce the generic versions once patents and exclusivity expire.
What are the potential risks or side effects associated with Belsomra?
Common side effects reported for Belsomra include drowsiness and headache [2]. More serious risks can include complex sleep behaviors such as sleep-walking, sleep-driving, and engaging in other activities while not fully awake, with no memory of the event. Patients are advised to discontinue use and seek medical attention if these behaviors occur [2].
How does Belsomra compare to other insomnia medications?
Belsomra belongs to a class of drugs called orexin receptor antagonists, which is distinct from older classes like benzodiazepines and non-benzodiazepine hypnotics. Its mechanism focuses on reducing the drive to stay awake, rather than directly inducing sleep through sedation [2].
Sources:
[1] DrugPatentWatch.com
[2] Belsomra Prescribing Information
[3] U.S. Food & Drug Administration
[4] Merck & Co., Inc.